This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Randomized, Double-blind, Placebo-controlled, Pa...
Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable A

Read time: 1 mins
Last updated:12th Apr 2013
The primary objectives of this study are to assess the safety and the efficacy of 2 doses of once daily EVP-6124 tablets (1 and 2 mg) as an adjunctive pro-cognitive treatment, versus placebo, when added to chronic, stable, atypical antipsychotic therapy in subjects with schizophrenia. Safety will be determined by clinical and laboratory safety assessments and efficacy will be determined by cognitive function as measured by the MCCB overall cognitive index, and by clinical function as measured by the interview-based SCoRS.
Category Value
Study start date 2013-04-12

View full details